In a strategic move to address the escalating demand for its diabetes and obesity therapies, Novo Nordisk, a global healthcare company, has announced a significant investment of EUR 2.1 billion (USD 2.3 billion) in expanding its manufacturing facility in Chartres, France. This capital infusion aligns with Novo Nordisk’s commitment to increasing production capacity for key